Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis

Thromb Res. 1989 Jul 1;55(1):5-11. doi: 10.1016/0049-3848(89)90451-9.

Abstract

Patients with symptoms of deep vein thrombosis for less than 10 days were treated with a standard dose of heparin. In the open label phase of the trial, 11 patients received 100 mg rt-PA on the first day and 50 mg on the subsequent day in an 8 hour infusion. In the double-blind phase, 8 patients were randomized to the same rt-PA regimen, 6 patients to an infusion of 50 mg rt-PA over 8 hours on days 1 and 2, and 7 patients to placebo infusions. The mean change in venographic score in all patients treated with rt-PA plus heparin is -3.8 units compared to -0.6 units in patients treated with heparin alone (p = 0.06). Bleeding complications classified as major were noted in 8/25 patients receiving the combined treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Heparin / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Pelvis
  • Pilot Projects
  • Random Allocation
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Thrombophlebitis / drug therapy*
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Recombinant Proteins
  • Heparin
  • Tissue Plasminogen Activator